ABSTRACT
OBJECTIVE@#To investigate the effects of Weikang Capsule (, WKC) on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy (MCCE).@*METHODS@#Patients taking enteric-coated aspirin aged 40-75 years were enrolled in Beijing Anzhen Hospital, Capital Medical University from January 2019 to December 2019. The patients continued taking aspirin Tablet (100 mg per day) and underwent MCCE before and after 1-month combined treatment with WKC (0.9 g per time orally, 3 times per day). The gastrointestinal symptom score, gastric Lanza score, the duodenal, jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment. Adverse events including nausea, vomiting, abdominal pain, abdominal distension, abdominal discomfort, dizziness, or headache during MCCE and combined treatment were observed and recorded.@*RESULTS@#Twenty-two patients (male/female, 13/9) taking enteric-coated aspirin aged 59.5 ± 11.3 years with a duration of aspirin use of 28.0 (1.0, 48.0) months were recruited. Compared with pre-treatment, the gastrointestinal symptom rating scale scores, gastric Lanza scores, and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment (P<0.05), and jejunal and ileal mucosal injury scores showed no obvious change. No adverse events occurred during the trial.@*CONCLUSIONS@#WKC can alleviate gastrointestinal symptoms, as well as gastric and duodenal mucosal injuries, in patients taking enteric-coated aspirin; it does not aggravate jejunal or ileal mucosal injury, which may be an effective alternative for these patients (Clinical trial registry No. ChiCTR1900025451).
ABSTRACT
Objective To explore and analyze the clinical curative effect and prognosis of enteric -coated aspirin combined with clopidogrel in the treatment of unstable angina pectoris of coronary heart disease.Methods 84 patients with unstable coronary heart disease angina pectoris were selected in the research,and they were divided into regular treatment group and combination group,42 cases in each group.The patients in conventional treatment group were given enteric -coated aspirin therapy,and the combined treatment group were given clopidogrel on the basis of routine treatment.The myocardial enzymology indexes of 24h before and after drug treatment,electrocardio-gram (ECG)recovery,curative effect and adverse reaction were compared between the two groups.Results After treatment,the myocardial enzymology indexes of the combined treatment group (AST,CK -MB,cTnT,cTnI)had sig-nificant differences compared with the general treatment group (t =3.98,P 0.05).Conclusion Drug combination therapy in the treatment of unstable type of coronary heart disease angina pectoris can synergistically improve clinical symptoms and physical fitness,improve patients'quality of life,it is safe and reliable,which is worth popularization and application widely.
ABSTRACT
OBJECTIVE: To explore the clinical efficacy of irbesartan, enteric-coated aspirin combined with tetramethylpyrazine in the treatment of diabetic nephropathy. METHODS: 75 patients with diabetic nephropathy were randomly divided into treatment group(n=40) and control group(n=35). Both groups were administered with 150 mg irbesartan(p.o.) and 100 mg enteric-coated aspirin (p.o.) once a day. Treatment group were additionally treated with 0.9% normal saline containing 200 mg tetramethylpyrazine once a day (i.v.gtt). During 28 days of treatment, treatment group was compared with control group in respect of 24-h urine protein, blood lipids, blood rheology. RESULTS: After treatment, hemorheological indexes (?b, EAI), renal function indexes(Scr、BUN、24-h urine protein) , Serum lipids(TG, TC) were decreased significantly(P
ABSTRACT
BACKGROUND: The role of platelet in the pathogenesis of acute coronary syndrome and cerebral thrombosis is well known and the platelet inhibitors are used widely for primary and sccondary prevention of cardiovascular disease. Aspirin is the least expensive and most widely used antiplatelet agent and its effect is associated with its ability to inhibit plateletthromboxane A2 synthesis. The effectiveness of aspirin is dependent on its ability to block the formation of thromboxane A2. Ticlopidine is another popular antiplatelet agent used today in the era of stent implantation for treating coronary artery obstructive disease(CAOD) with aspirin. The mechanism of action of ticlopidine is clearly different from that of aspirin. It is concluded recently that ticlopidine is an inhibitor of ADP binding to platelets. The inhibition of ADP binding to platelets by ticlopidine is very nicely correlated with its does and the inhibition of platelet aggregation. Therefore, in this study, antiplatelet effect of low dose enteric-coated aspirin in place of aspirin and combined therapy with low does enteric-coated aspirin plus ticlopidine were evaluated in the normal subjects. METHOD: IN twenty normal subjects, platelet aggregation tests with adenosine diphosphate(ADP) and collagen were performed baseline, after I week adminisrtation of enteric-coated aspirin, and in randomly selected ten among twenty normal subjects, I week administration of enteric-coated aspirin and ticlopidine. The maximal aggregation rate was calculated by measuring the maximal change of the light transmittance after addition of aggregating agents. RESULT: Low does enteric-coated aspirin inhibited platelet aggregation in response to collagen significantly. Less than 25% of antiaggregation effect was noted in about 50% of subjects with low dose enteric-coated aspirin when platelet aggregation was induced by ADP. Ticlopidine in combination with low does enteric-coated aspirin potentiated the inhibitory effect significantly on platelet aggregation in response to ADP. CONCLUSION: Effect of low dose enteric-coated aspirin alone on platelet aggregation in response to ADP stimulation was weak and showed variablity, comparing to collagen stimulation. The combined treatment of ticlopidine plus aspirin was synergistically inhibited platelet aggregation responding to ADP stimulation. Therefore to achieve the synergistic inhibition of platelet aggregation to ADP and collagen stimulation, combination theraphy might be a effective regimen.